Top Markets
#1 Black Phoenix Black Phoenix +354.09%
#2 Akedo Akedo +105.75%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +58.06%
#5 Acurast Acurast +40.10%
#6 OpenEden OpenEden +39.66%
#7 BasedHype BasedHype +27.11%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.53%
#9 Cryptopia Cryptopia +21.54%
#10 Bedrock Bedrock +19.76%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Purple Biotech Ltd. Purple Biotech Ltd.

Purple Biotech Ltd.

PPBT
Classifica tra le azioni #40641
Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies... Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1). Currently in Phase 2 clinical trials, CM24 is being investigated as a combination therapy with anti-PD-1 checkpoint inhibitors for treating pancreatic ductal adenocarcinoma. Another candidate is NT219, a small molecule compound in Phase 1/2 clinical trials, which functions by inhibiting insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT). This compound is being developed for recurrent and/or metastatic squamous cell carcinoma of the head and neck, or colorectal adenocarcinoma. Furthermore, IM1240, a multi-valent antibody designed to activate an anti-tumoral immune response against 5T4-positive tumors, is in its preclinical stage. The company has established significant collaborations, including an agreement with Bristol Myers Squibb Company for Phase 2 clinical trials to assess CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy, as well as a partnership with Mor Research Applications. Formerly known as Kitov Pharma Ltd., the company adopted the name Purple Biotech Ltd. in December 2020 and is headquartered in Rehovot, Israel.
Prezzo delle azioni
$0.00323826
Ultima sincronizzazione: 2026-08-12
Capitalizzazione di mercato
$104.81K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-70.42%
Paese
IL
Scambia Purple Biotech Ltd. (PPBT)

Categoria

Healthcare
Ricavi di Purple Biotech Ltd. (PPBT)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Purple Biotech Ltd., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Purple Biotech Ltd. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE